Skip to main content

Table 3 Costs by cost category, mean costs and cost differences discounted, adjusted and unadjusted, given in € (2015)

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

 

mean costs (SD) per patient

 

category

standard (IMRT only) [€]

SD (IMRT only)

experimental (IMRT + C12) [€]

SD (IMRT + C12)

mean cost difference [€]

95% CI, non-parametric bootstrapping (€)

p-value

initial treatment

5.68

17.88

11.2

 

diagnostic follow-up

2.66

1.47

3

1.11

332

− 219; 955

0.165

treatment of recurrence

 surgery

2.03

6.37

4.82

8.35

2.78

8; 6.039

0.002

 re-RT

2.18

4.92

4.93

11.98

2.75

− 813; 6.376

0.179

 chemotherapy

3.03

3.42

2.46

3.3

− 572

− 2023; 834

0.378

 palliative RT

105

287

103

267

−3

− 131; 105

0.688

total complication costs

7.35

8.51

12.31

16.99

4.95

192; 10,501

0.019

mean total costs (unadjusted)

 undiscounted

15.76

9.17

33.97

17.55

18.15

12,770; 23,745

0.000

 3.5% discount p.a.

14.75

7.95

32.86

14.83

18,076

13,416; 22,922

0.000

 3.0% discount p.a.

14.88

8.1

32.13

15.18

17.25

12,551; 21,946

0.000

mean total costs (adjusted Lin1)

 adjusted (3 monthly intervals)

16.16

 

38.98

 

22.82

  

 adjusted annually

12.11

 

36.71

 

24.6

  

 3.5% discount p.a.

11.68

 

33.71

 

22.03

  

 3.0% discount p.a.

11.74

 

34.09

 

22.35